CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
26 juin 2024 10h52 HE
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH's distributor
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
17 juin 2024 09h50 HE
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation.
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
05 juin 2024 15h12 HE
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
“Collaboration in clinical trials ensures data integrity and safety, advancing both organizations' missions and improving patient care,” says Dr. Jennifer
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
28 mai 2024 08h00 HE
|
HiberCell, Inc.
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
05 avr. 2024 10h00 HE
|
HiberCell, Inc.
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
27 mars 2024 08h00 HE
|
Vector Pharma FZCO; Oncopeptides AB
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE (BNTX)
16 janv. 2024 15h27 HE
|
Robbins LLP
BioNTech SE (BNTX) Allegedly Misled Investors Regarding its Business Prospects
Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. est une nouvelle société créée par Catalys Pacific, et dans laquelle Inventiva détient une participation de 30%. Dans le cadre de l’accord de licence exclusif, Inventiva...
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million...
Truveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta’s Community to Accelerate Recruitment to Povetacicept Clinical Trials
22 mars 2023 08h45 HE
|
Truveta
BELLEVUE and SEATTLE, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Today, Truveta and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced a strategic partnership to help accelerate clinical trial...